GoutPhase 2NCT05499312
An Innovative Chinese Herbal Formula for the Treatment of Gout
A Phase 2 study testing HKIIM-KU formula in people with Gout, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Gout
- What is being tested?
- HKIIM-KU formula
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteHong Kong
- Study dates
- 11 Oct 2022to 27 Aug 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient meeting the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2015 gout classification criteria (met sufficient criterion* or total score ≥8) ;
- History of >=1 self-reported flare of gouty arthritis within 12 months prior to randomization;
- Agree to undergo blood test and willing to complete questionnaires and take medications as scheduled; and
- Agree to participate in the study and provide written informed consent. (for those illiterate subjects, their family member can sign the consent form upon subject's agreement) Note: * Sufficient criterion = Presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus
Who cannot join
- Liver-kidney yin deficiency pattern according to Chinese medicine theory;
- Use of urate-lowering drugs within 2 weeks prior to screening;
- Present of tophi or known history of kidney stones.
- Known use of oral/injectable corticosteroids or other Chinese herbal medicine for treating gout within 1 month prior to screening;
- Ongoing acute gout arthritis flare at screening or within 2 weeks prior to screening;
- History of >4 flares overall in the 12 months prior to screening.
Show all 15Show fewer
- Polyarticular gouty arthritis involving more than 4 joints;
- Severe deformity, stiffness and labor loss of patients with advanced arthritis;
- Known rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis;
- Known history of any serious diseases such as severe kidney and liver impairments, autoimmune disease, thyroid disease, Hodgkin's disease, lymphoma, severe mental disorders and leukemia
- Known presence or suspicion of acute infectious disease;
- Known history of malignancy within the past 5 years;
- Known allergic to the drug used in this study;
- Documented pregnant or lactation;
- Subjects participating in other clinical studies at the same time.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy and Safety of an Innovative Chinese Herbal Formula for the Treatment of Gout: A Double-blind, Randomized, Placebo-Controlled Trial
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide annually.
The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.
Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.
Read the detailed description
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders. Gout affects a significant portion of the population worldwide annually. According to a recent meta-analysis, the prevalence of gout world-wide is 0.6%, while there was marked statistical heterogeneity geographically resulting of a prevalence ranging from <1% to 6.8%. The frequent attack of gout not only seriously affect the life of patients, but also lead to disability.
There are a few disease states of gout including asymptomatic hyperuricaemia, acute gouty arthritis, intercritical period, and chronic gouty arthritis. Acute flare of gout is characterized by inflamed joint arthritis which peaks within hours with signs of inflammation including redness, hotness, tenderness, swelling and loss of function. The acute attack usually resolves in 2 weeks and the patient enter into a remission phase called intercritical period. There are usually no symptoms during this period, however, proper treatment for hyperuricaemia is needed to prevent further acute attack of gout. Untreated gout or hyperuricaemia will progress into destruction of joints with formation of tophi which are accumulated monosodium urate (MSU) crystals. Joint destruction and deformity are the untreated results of gout, leading to great distress and disability.
The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. It has been found that environment, genetics, immunity, diet, internal environment, trauma and stimulation are involved in the pathogenesis in various degrees. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. The mechanism of these drugs is to reduce joint inflammation, pain and uric acid level. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. For example, Benzbromarone may cause severe renal damage. Moreover, various studies have found a strong association between human leukocyte antigen-B*58:01 (HLA-B*58:01) and allopurinol-induced severe cutaneous adverse reactions especially in Han Chinese. With such genetic predisposition, patients may develop toxic epidermal necrolysis, Steven Johnson syndrome and other life-threatening immune-mediated severe cutaneous adverse reactions with allopurinol use. It is reported that the carrier rate of the HLA-B*58:01 allele was 14% in Han Chinese in Hong Kong. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.
Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. In Traditional Chinese medicine (TCM), gout is classified as Bi pattern usually due to Qi stagnation in the meridians and collaterals. Among them, Zhu Liangchun Gout Decoction is one of the most commonly used formulae. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. The formula was based on Zhu Liangchun Gout Decoction and has been modified to suit gout patients in Hong Kong. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.
- Conditions
- Gout
- Being tested
- HKIIM-KU formula, Placebo
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HKIIM-KU formulaDrug
Also called HKIIM-KU
Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
PlaceboDrug
Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| HKIIM-KU formula | Experimental | Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks. Receives: Drug: HKIIM-KU formula |
| Placebo | Placebo comparator | Subjects will receive placebo granules (16.9g twice daily) for 8 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum uric acid
Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.
Measured: week 4
Serum uric acid
Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.
Measured: week 8
Secondary outcomes (19)
Serum uric acid
Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.
Measured: week 12
Pain Visual Analogue Scale
Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.
Measured: week 2
Pain Visual Analogue Scale
Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.
Measured: week 4
Pain Visual Analogue Scale
Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.
Measured: week 8
Pain Visual Analogue Scale
Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.
Measured: week 12
Health Assessment Questionnaire Disability Index
HAQ-DI is a validated tool for measuring physical function in patients with gout.
Measured: week 2
Health Assessment Questionnaire Disability Index
HAQ-DI is a validated tool for measuring physical function in patients with gout.
Measured: week 4
Health Assessment Questionnaire Disability Index
HAQ-DI is a validated tool for measuring physical function in patients with gout.
Measured: week 8
Health Assessment Questionnaire Disability Index
HAQ-DI is a validated tool for measuring physical function in patients with gout.
Measured: week 12
Short Form-36
Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.
Measured: week 2
Short Form-36
Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.
Measured: week 4
Short Form-36
Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.
Measured: week 8
Short Form-36
Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.
Measured: week 12
No. of patients with new flare
Number of patients with at least one new gout flare after baseline
Measured: Up to week 12
Time to first new flare
Time to the first new gout flare
Measured: Up to week 12
Number of patients using rescue medication
Number of patients using rescue medication (i.e. paracetamol) after baseline
Measured: Up to week 12
Time to first use of rescue medication
Time to first use of rescue medication after baseline
Measured: Up to week 12
Adverse events
Adverse events related to study treatment will be recorded.
Measured: Up to week 12
Clinical pattern/syndrome according to Chinese medicine theory
Subjects will be assessed by Registered Chinese Medicine Practitioners (RCMPs) under Chinese medicine theory in this trial. A form will be used to record the clinical pattern/syndrome on each visit by the RCMP according to Chinese medicine theory.
Measured: Up to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2022
- Study start11 Oct 2022
- Primary completion27 Aug 2024
- Study completion27 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GoutStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Lin Zhixiu, Chinese University of Hong Kong
- Investigators
- Zhixiu LIN, PhD, Principal investigator, Hong Kong Institute of Integrative Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05499312
- Sponsor's protocol ID
- Gout Study
- Status last verified
- Jul 2026
- First submitted
- 10 Aug 2022
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of an Innovative Chinese Herbal Formula for the Treatment of Gout: A Double-blind, Randomized, Placebo-Controlled Trial
- ClinicalTrials.gov ID
- NCT05499312
- Acronym / sponsor ID
- Gout Study
- Conditions
- Gout
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 11 Oct 2022 (actual)
- Primary completion
- 27 Aug 2024 (actual)
- Study completion
- 27 Aug 2024 (actual)
- First posted
- 12 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide annually.
The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.
Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.
Detailed description
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders. Gout affects a significant portion of the population worldwide annually. According to a recent meta-analysis, the prevalence of gout world-wide is 0.6%, while there was marked statistical heterogeneity geographically resulting of a prevalence ranging from <1% to 6.8%. The frequent attack of gout not only seriously affect the life of patients, but also lead to disability.
There are a few disease states of gout including asymptomatic hyperuricaemia, acute gouty arthritis, intercritical period, and chronic gouty arthritis. Acute flare of gout is characterized by inflamed joint arthritis which peaks within hours with signs of inflammation including redness, hotness, tenderness, swelling and loss of function. The acute attack usually resolves in 2 weeks and the patient enter into a remission phase called intercritical period. There are usually no symptoms during this period, however, proper treatment for hyperuricaemia is needed to prevent further acute attack of gout. Untreated gout or hyperuricaemia will progress into destruction of joints with formation of tophi which are accumulated monosodium urate (MSU) crystals. Joint destruction and deformity are the untreated results of gout, leading to great distress and disability.
The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. It has been found that environment, genetics, immunity, diet, internal environment, trauma and stimulation are involved in the pathogenesis in various degrees. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. The mechanism of these drugs is to reduce joint inflammation, pain and uric acid level. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. For example, Benzbromarone may cause severe renal damage. Moreover, various studies have found a strong association between human leukocyte antigen-B*58:01 (HLA-B*58:01) and allopurinol-induced severe cutaneous adverse reactions especially in Han Chinese. With such genetic predisposition, patients may develop toxic epidermal necrolysis, Steven Johnson syndrome and other life-threatening immune-mediated severe cutaneous adverse reactions with allopurinol use. It is reported that the carrier rate of the HLA-B*58:01 allele was 14% in Han Chinese in Hong Kong. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.
Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. In Traditional Chinese medicine (TCM), gout is classified as Bi pattern usually due to Qi stagnation in the meridians and collaterals. Among them, Zhu Liangchun Gout Decoction is one of the most commonly used formulae. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. The formula was based on Zhu Liangchun Gout Decoction and has been modified to suit gout patients in Hong Kong. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HKIIM-KU formula | Experimental | Drug: HKIIM-KU formulaSubjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboSubjects will receive placebo granules (16.9g twice daily) for 8 weeks. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patient meeting the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2015 gout classification criteria (met sufficient criterion* or total score ≥8) ;
- History of >=1 self-reported flare of gouty arthritis within 12 months prior to randomization;
- Agree to undergo blood test and willing to complete questionnaires and take medications as scheduled; and
- Agree to participate in the study and provide written informed consent. (for those illiterate subjects, their family member can sign the consent form upon subject's agreement) Note: * Sufficient criterion = Presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus
Key exclusion criteria (15 listed)
- Liver-kidney yin deficiency pattern according to Chinese medicine theory;
- Use of urate-lowering drugs within 2 weeks prior to screening;
- Present of tophi or known history of kidney stones.
- Known use of oral/injectable corticosteroids or other Chinese herbal medicine for treating gout within 1 month prior to screening;
- Ongoing acute gout arthritis flare at screening or within 2 weeks prior to screening;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HKIIM-KU formulaAlso: HKIIM-KUSubjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks. | Drug | HKIIM-KU formula |
| PlaceboSubjects will receive placebo granules (16.9g twice daily) for 8 weeks. | Drug | Placebo |
Primary outcome
Serum uric acid
Time frame: week 4
Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.
Serum uric acid
Time frame: week 8
Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.
19 secondary outcomes
Serum uric acid
Time frame: week 12
Pain Visual Analogue Scale
Time frame: week 2
Pain Visual Analogue Scale
Time frame: week 4
Pain Visual Analogue Scale
Time frame: week 8
Pain Visual Analogue Scale
Time frame: week 12
Health Assessment Questionnaire Disability Index
Time frame: week 2
Health Assessment Questionnaire Disability Index
Time frame: week 4
Health Assessment Questionnaire Disability Index
Time frame: week 8
Health Assessment Questionnaire Disability Index
Time frame: week 12
Short Form-36
Time frame: week 2
Short Form-36
Time frame: week 4
Short Form-36
Time frame: week 8
Short Form-36
Time frame: week 12
No. of patients with new flare
Time frame: Up to week 12
Time to first new flare
Time frame: Up to week 12
Number of patients using rescue medication
Time frame: Up to week 12
Time to first use of rescue medication
Time frame: Up to week 12
Adverse events
Time frame: Up to week 12
Clinical pattern/syndrome according to Chinese medicine theory
Time frame: Up to week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
Related trials for Gout
RecruitingPhase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Enrolling by invitation
The Remote Monitoring of Gout Study
Gout Initiating Urate-loweringUrate-lowering Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhixiu LIN, PhD principal investigator
Hong Kong Institute of Integrative Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing HKIIM-KU formula in people with Gout, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum uric acid (time frame: week 4). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.